Download PDF
Thromb Haemost 1986; 56(03): 250-255
DOI: 10.1055/s-0038-1661660
Original Article
Schattauer GmbH Stuttgart

An Enzyme Immunoassay (ELISA) for the Quantitation of Human Factor VII

C Boyer
The Laboratoire Central d′Hématologie and INSERM U.143, Hôpital Bicêtre, le Kremlin-Bicêtre, France
,
M Wolf
The Laboratoire Central d′Hématologie and INSERM U.143, Hôpital Bicêtre, le Kremlin-Bicêtre, France
,
C Rothschild
The Laboratoire Central d′Hématologie and INSERM U.143, Hôpital Bicêtre, le Kremlin-Bicêtre, France
,
M Migaud
*   The Diagnostica Stago, Asnières, France
,
J Amiral
*   The Diagnostica Stago, Asnières, France
,
P M Mannucci
**   A. Bianchi Bonomi, Hemophilia and Thrombosis Center, University of Milano, Italy
,
D Meyer
The Laboratoire Central d′Hématologie and INSERM U.143, Hôpital Bicêtre, le Kremlin-Bicêtre, France
,
M J Larrieu
The Laboratoire Central d′Hématologie and INSERM U.143, Hôpital Bicêtre, le Kremlin-Bicêtre, France
› Author Affiliations
Further Information

Publication History

Received 21 May 1986

Accepted after revision 12 August 1986

Publication Date:
18 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A new solid phase enzyme-linked immunosorbent assay (ELISA) was developed for the quantitation of human Factor VII antigen (F VII Ag), using a monospecific rabbit anti-F VII antiserum. Anti-F VII F(ab′)2 fragments were adsorbed to polystyrene plates. The binding of serial dilutions of control or test plasma, containing F VII, was detected by incubation with peroxidase-labeled anti- FV II IgG followed by the addition of hydrogen peroxyde and O-phenylenediamine. This ELISA is specific, sensitive (detection limit: 0.05%) and accurate (coefficient of variation: 1.5-4% for within- and 1.6-9% for between-assays). F VII coagulant activity (F VII C) and F VII Ag were determined in large populations of controls and patients. In normal plasma (n = 38), F VII Ag ranged from 83 to 117% and the correlation coefficient between F VII Ag and F VII C was 0.94. In patients with severe (F VII C inf. 1%) congenital F VII deficiency (n = 5), F VII Ag was undetectable in two cases (inf. 0.05%) and markedly reduced (0.35 to 5.6%) in the three other cases. In patients with liver cirrhosis (n = 15), F VII Ag ranged from 21 to 59% and was in good correlation with F VII C (r = 0.84). In dicoumarol treated patients (n = 15), the levels of F VII Ag ranged from 51% to 79% and a poor correlation (r = 0.52) with F VIIC was observed. In “compensated” DIC (n = 5), levels of F VII Ag varied from 60 to 186%, with significantly higher F VII C levels (from 143 to 189%). In contrast, in “decompensated” DIC (n = 7), low F VII Ag and F VII C levels were observed (from 7 to 27%). In patients with deep-vein thrombosis (n = 25), high levels of F VII Ag (from 102 to 136%) and F VII C (from 110 to 150%) were demonstrated. In surgical patients, no significant difference was observed before and one day after intervention.

Key words

Factor VII - Congenital deficiency - Acquired deficiency - ELISA
 

  • References

  • 1 Bajaj SP, Rapaport SI, Brown SF. Isolation and characterization of human factor VII. J Biol Chem 1981; 256: 253-259
    PubMedGoogle Scholar
  • 2 Nemerson Y, Furie B. Zymogens and cofactors of blood coagulation. CRC Crit Rev Biochem 1980; 9: 45-49
    PubMedGoogle Scholar
  • 3 Kisiel W, McMullen BA. Isolation and characterization of human factor VIIa. Thromb Res 1981; 22: 375-380
    CrossrefPubMedGoogle Scholar
  • 4 Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci USA 1977; 74: 5260-5264
    CrossrefPubMedGoogle Scholar
  • 5 Mariani G, Mazzucconi MG, Hermans J, Ciavarella N, Faiella A, Hassan HJ, Mannucci PM, Nenci GG, Orlando M, Romoli D, Mandelli F. Factor VII deficiency: immunological characterization of genetic variants and detection of carriers. Br J Haematol 1981; 48: 7-14
    PubMedGoogle Scholar
  • 6 Briet E, Loeliger EA, Van Tilburg NH, Veltkamp JJ. Molecular variants of factor VII. Thromb Haemostas 1976; 35: 289-294
    PubMedGoogle Scholar
  • 7 Goodnight SH, Feinstein DI, Osterud B, Rapaport SI. Factor VII antibody-neutralizing material in hereditary and acquired factor VII deficiency. Blood 1971; 38: 1-8
    PubMedGoogle Scholar
  • 8 Girolami A, Fabris F, Dalbozanon R, Ghiotto G, Burul A. Factor VII Padua: a coagulation disorder due to an abnormal factor VII with a peculiar activation pattern. J Lab Clin Med 1978; 91: 387-395
    PubMedGoogle Scholar
  • 9 Mazzucconi MG, Mandelli F, Mariani G, Briet E, Veltkamp JJ. A CRM positive variant of factor VII deficiency and the detection of heterozygotes with the assay of factor like antigen. Br J Haematol 1977; 36: 127-135
    CrossrefPubMedGoogle Scholar
  • 10 Nemerson Y. Regulation of the initiation of coagulation by factor VII. Haemostasis 1983; 13: 150-155
    PubMedGoogle Scholar
  • 11 Osterud B. How to measure factor VII and factor VII activation. Haemostasis 1983; 13: 161-168
    PubMedGoogle Scholar
  • 12 Fair DS. Quantitation of factor VII in the plasma of normal and warfarin-treated individuals by radioimmunoassay. Blood 1983; 62: 784-791
    PubMedGoogle Scholar
  • 13 Broze Jr GJ, Hickman S, Miletich JP. Monoclonal anti-human factor VII antibodies. Detection in plasma of a second protein antigenically and genetically related to factor VII. J Clin Invest 1985; 76: 937-946
    CrossrefPubMedGoogle Scholar
  • 14 Mazzuconi MG, Orlando M, Hassan HJ, Romoli D, Mariani G. Factor VII activity and cross reacting material in normal individuals. Thromb Res 1979; 14: 241-244
    CrossrefPubMedGoogle Scholar
  • 15 Boyer C, Wolf M, Lavergne JM, Larrieu MJ. Thrombin generation and formation of thrombin-antithrombin III complexes in congenital antithrombin III deficiency. Thromb Res 1980; 20: 207-218
    CrossrefPubMedGoogle Scholar
  • 16 Boyer C, Rothschild C, Wolf M, Amiral J, Meyer D, Larrieu MJ. A new method for the estimation of protein C by ELISA. Thromb Res 1984; 36: 579-589
    CrossrefPubMedGoogle Scholar
  • 17 Francis RB, Patch MJ. A functional assay for protein C in human plasma. Thromb Res 1983; 32: 605-613
    CrossrefPubMedGoogle Scholar
  • 18 Broze Jr GJ, Majerus PW. Purification and properties of human coagulation factor VII. J Biol Chem 1980; 255: 1242-1247
    PubMedGoogle Scholar
  • 19 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275
    PubMedGoogle Scholar
  • 20 Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-4412
    PubMedGoogle Scholar
  • 21 Nakane PK, Kawaoi A. Peroxidase labeled antibody: a new method of conjugation. J Histochem Cytochem 1974; 22: 1084-1091
    CrossrefPubMedGoogle Scholar
  • 22 Laurell CB. Antigen-antibody crossed electrophoresis. Anal Biochem 1965; 10: 358-361
    CrossrefPubMedGoogle Scholar
  • 23 Mannucci PM, Vigano S. Deficiencies of protein C, an inhibitor of blood coagulation. Lancet 1982; 28: 463-467
    PubMedGoogle Scholar
  • 24 Levanon M, Rimon S, Shani M, Ramot B, Goldberg E. Active and inactive factor VII in Dubin-Johnson syndrome with factor VII deficiency and on coumadin administration. Br J Haematol 1972; 23: 669-677
    CrossrefPubMedGoogle Scholar
  • 25 Howarth DJ, Brozovic M, Stirling Y, Reed M. Factor VII during warfarin treatment. Scand J Haematol 1974; 12: 346
    PubMedGoogle Scholar
  • 26 Mariani G, Mazzucconi MG, Solinas S, Awisati G, Chistolini A, Moretti T. Studies on PIVKA VII. Haemostasis 1984; 14: 238-243
    PubMedGoogle Scholar
  • 27 Triplett DA, Brandt JT, McGann Batard MA, Schaeffer Dixon JL, Fair DS. Hereditary factor VII deficiency: heterogeneity defined by combined functional and immunochemical analysis. Blood 1985; 66: 1284-1287
    PubMedGoogle Scholar
  • 28 Brozovic M, Stirling Y, Harricks C, North WR S, Meade TW. The factor VII in an industrial population. Br J Haematol 1974; 28: 381
    CrossrefPubMedGoogle Scholar
  • 29 Gjønnaess H. Cold promoted activation of factor VII. Evidence for the existence of an activator. Thromb Diath Haemorrh 1972; 28: 155-168
    PubMedGoogle Scholar
  • 30 Blanchard R A, Furie BC, Jorgensen M, Kruger SF, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med 1981; 305: 242-248
    CrossrefPubMedGoogle Scholar
  • 31 Vigano S, Mannucci PM, Solinas S, Bottasso B, Mariani G. Decreased in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol 1984; 57: 213-220
    CrossrefPubMedGoogle Scholar
  • 32 Johnson Jr CL, Hjort PF. Development of increased factor VII activity during the spontaneous coagulation of blood. J Clin Invest 1961; 40: 743-751
    CrossrefPubMedGoogle Scholar
  • 33 Seligsohn U, Osterud B, Rapaport SI. Coupled amidolytic assay for factor VII; its use with a clotting assay to determine the activity state of factor VII. Blood 1978; 52: 978-988
    PubMedGoogle Scholar
  • 34 Radcliffe R, Nemerson Y. The activation and control of factor VII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor VII. J Biol Chem 1975; 250: 388-395
    PubMedGoogle Scholar
  • 35 Brozovic M. Physiological mechanisms in coagulation and fibrinolysis. Br Med Bull 1977; 33: 231-238
    CrossrefPubMedGoogle Scholar
  • 36 Meade TW. Factor VII and ischaemic heart disease: epidemiological evidence. Haemostasis 1983; 13: 178-185
    PubMedGoogle Scholar